X4 Pharmaceuticals announces positive top-line results for WHIM Syndrome drug
X4 Pharmaceuticals has announced positive top-line results from a Phase 3 study of its lead investigational therapy, mavorixafor, in people with warts, hypogammaglobulinemia, infections, and myelok...